These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 15688284)

  • 21. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers.
    Bhamarapravati N; Yoksan S; Chayaniyayothin T; Angsubphakorn S; Bunyaratvej A
    Bull World Health Organ; 1987; 65(2):189-95. PubMed ID: 3496985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers.
    Wright PF; Ankrah S; Henderson SE; Durbin AP; Speicher J; Whitehead SS; Murphy BR; Pletnev AG
    Vaccine; 2008 Feb; 26(7):882-90. PubMed ID: 18207289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
    Capeding RZ; Luna IA; Bomasang E; Lupisan S; Lang J; Forrat R; Wartel A; Crevat D
    Vaccine; 2011 May; 29(22):3863-72. PubMed ID: 21477675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
    Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS
    BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
    Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
    J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
    Bernstein DI; Malkin E; Abughali N; Falloon J; Yi T; Dubovsky F;
    Pediatr Infect Dis J; 2012 Feb; 31(2):109-14. PubMed ID: 21926667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.
    Ruiz-Palacios GM; Guerrero ML; Bautista-Márquez A; Ortega-Gallegos H; Tuz-Dzib F; Reyes-González L; Rosales-Pedraza G; Martínez-López J; Castañón-Acosta E; Cervantes Y; Costa-Clemens S; DeVos B
    Pediatrics; 2007 Aug; 120(2):e253-61. PubMed ID: 17606534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys.
    Blair PJ; Kochel TJ; Raviprakash K; Guevara C; Salazar M; Wu SJ; Olson JG; Porter KR
    Vaccine; 2006 Feb; 24(9):1427-32. PubMed ID: 16214271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
    Koraka P; Benton S; van Amerongen G; Stittelaar KJ; Osterhaus AD
    Vaccine; 2007 Jul; 25(29):5409-16. PubMed ID: 17560694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial.
    Bhandari N; Sharma P; Taneja S; Kumar T; Rongsen-Chandola T; Appaiahgari MB; Mishra A; Singh S; Vrati S;
    J Infect Dis; 2009 Aug; 200(3):421-9. PubMed ID: 19545211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.
    Morrison D; Legg TJ; Billings CW; Forrat R; Yoksan S; Lang J
    J Infect Dis; 2010 Feb; 201(3):370-7. PubMed ID: 20059357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
    Blaney JE; Hanson CT; Firestone CY; Hanley KA; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2004 Dec; 71(6):811-21. PubMed ID: 15642976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
    Belshe RB; Newman FK; Tsai TF; Karron RA; Reisinger K; Roberton D; Marshall H; Schwartz R; King J; Henderson FW; Rodriguez W; Severs JM; Wright PF; Keyserling H; Weinberg GA; Bromberg K; Loh R; Sly P; McIntyre P; Ziegler JB; Hackell J; Deatly A; Georgiu A; Paschalis M; Wu SL; Tatem JM; Murphy B; Anderson E
    J Infect Dis; 2004 Feb; 189(3):462-70. PubMed ID: 14745704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein.
    Mota J; Acosta M; Argotte R; Figueroa R; Méndez A; Ramos C
    Vaccine; 2005 May; 23(26):3469-76. PubMed ID: 15837370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.
    Durbin AP; Whitehead SS; Shaffer D; Elwood D; Wanionek K; Thumar B; Blaney JE; Murphy BR; Schmidt AC
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1267. PubMed ID: 21829748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
    Launay O; Sadorge C; Jolly N; Poirier B; Béchet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML
    Vaccine; 2009 Feb; 27(8):1184-91. PubMed ID: 19135496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys.
    Butrapet S; Rabablert J; Angsubhakorn S; Wiriyarat W; Huang C; Kinney R; Punyim S; Bhamarapravati N
    Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):589-99. PubMed ID: 12693596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans.
    Hoke CH; Malinoski FJ; Eckels KH; Scott RM; Dubois DR; Summers PL; Simms T; Burrous J; Hasty SE; Bancroft WH
    Am J Trop Med Hyg; 1990 Aug; 43(2):219-26. PubMed ID: 2389825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.
    Dayan GH; Bevilacqua J; Coleman D; Buldo A; Risi G
    Vaccine; 2012 Oct; 30(47):6656-64. PubMed ID: 22959989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.